恒瑞医药：瑞维鲁胺片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of Ruvelimab tablets, which will commence shortly [1] Group 1: Company Developments - The company has been granted a "Drug Clinical Trial Approval Notice" for Ruvelimab tablets [1] - Ruvelimab tablets are classified as a second-generation AR inhibitor, offering stronger AR inhibition compared to first-generation AR inhibitors [1] - The new drug is noted for having no agonistic effects, distinguishing it from earlier treatments [1]